GSK Ventolin HFA Switch From CFC Inhaler Has Comparable Asthma Efficacy
Executive Summary
GlaxoSmithKline Ventolin HFA labeling states that switching to the non-chlorofluorocarbon inhaler from a CFC-propelled product does not result in "any clinically significant changes in the efficacy profile."
You may also be interested in...
GSK Ventolin HFA roll-out
Ventolin CFC version of inhalation asthma agent will be phased out in next 10 to 15 months following Feb. 20 launch of albuterol HFA, GlaxoSmithKline said. Ventolin HFA's wholesale acquisition cost will be same as its successor: $29.99 for 100 mcg. Ventolin HFA was approved in April 2001 (1"The Pink Sheet" April 23, 2001, p. 34)...
GSK Ventolin HFA roll-out
Ventolin CFC version of inhalation asthma agent will be phased out in next 10 to 15 months following Feb. 20 launch of albuterol HFA, GlaxoSmithKline said. Ventolin HFA's wholesale acquisition cost will be same as its successor: $29.99 for 100 mcg. Ventolin HFA was approved in April 2001 (1"The Pink Sheet" April 23, 2001, p. 34)...
Glaxo Ventolin HFA phase-in
Non-chlorofluorocarbon albuterol inhaler Ventolin HFA will gradually replace existing CFC product following launch, GlaxoSmithKline says. Company is meeting with physicians and patients to determine the best way to implement the CFC phase-out. Ventolin HFA was approved April 12 (1"The Pink Sheet" April 23, p. 34)